سوق اختبارات الرعاية الصحية في تايلاند (POCT) - اتجاهات الصناعة وتوقعاتها حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THAILAND POINT-OF-CARE-TESTING (POCT) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE THAILAND POINT-OF-CARE-TESTING (POCT) SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET : RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 FUTURE OUTLOOK

11 REGULATORY COMPLIANCE

11.1 REGULATORY AUTHORITIES

11.2 REGULATORY CLASSIFICATIONS

11.2.1 CLASS I

11.2.2 CLASS II

11.2.3 CLASS III

11.3 REGULATORY SUBMISSIONS

11.4 INTERNATIONAL HARMONIZATION

11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

11.6 REGULATORY CHALLENGES AND STRATEGIES

12 OPPUTUNITY MAP ANALYSIS

13 HEALTHCARE ECONOMY

13.1 HEALTHCARE EXPENDITURE

13.2 CAPITAL EXPENDITURE

13.3 CAPEX TRENDS

13.4 CAPEX ALLOCATION

13.5 FUNDING SOURCES

13.6 INDUSTRY BENCHMARKS

13.7 GDP RATION IN OVERALL GDP

13.8 HEALTHCARE SYSTEM STRUCTURE

13.9 GOVERNMENT POLICIES

13.1 ECONOMIC DEVELOPMENT

14 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PRODUCT TYPE

14.1 OVERVIEW

14.2 CARDIOMETABOLIC MONITORING PRODUCTS

14.2.1 CARDIAC MARKER TESTING PRODUCTS

14.2.1.1. HSTNL

14.2.1.1.1. MARKET VALUE (USD MILLION)

14.2.1.1.2. MARKET VOLUME (UNITS)

14.2.1.1.3. AVERAGE SELLING PRICE (USD)

14.2.1.2. BNP

14.2.1.2.1. MARKET VALUE (USD MILLION)

14.2.1.2.2. MARKET VOLUME (UNITS)

14.2.1.2.3. AVERAGE SELLING PRICE (USD)

14.2.1.3. D-DIMER

14.2.1.3.1. MARKET VALUE (USD MILLION)

14.2.1.3.2. MARKET VOLUME (UNITS)

14.2.1.3.3. AVERAGE SELLING PRICE (USD)

14.2.1.4. CK-MB

14.2.1.4.1. MARKET VALUE (USD MILLION)

14.2.1.4.2. MARKET VOLUME (UNITS)

14.2.1.4.3. AVERAGE SELLING PRICE (USD)

14.2.1.5. MYOGLOBIN

14.2.1.5.1. MARKET VALUE (USD MILLION)

14.2.1.5.2. MARKET VOLUME (UNITS)

14.2.1.5.3. AVERAGE SELLING PRICE (USD)

14.2.1.6. OTHERS

14.2.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS

14.2.2.1. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES

14.2.2.1.1. CARTRIDGES

14.2.2.1.1.1 MARKET VALUE (USD MILLION)

14.2.2.1.1.2 MARKET VOLUME (UNITS)

14.2.2.1.1.3 AVERAGE SELLING PRICE (USD)

14.2.2.1.2. REAGENTS

14.2.2.1.2.1 MARKET VALUE (USD MILLION)

14.2.2.1.2.2 MARKET VOLUME (UNITS)

14.2.2.1.2.3 AVERAGE SELLING PRICE (USD)

14.2.2.2. BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS

14.2.2.2.1. BENCHTOP

14.2.2.2.1.1 BLOOD GAS ANALYZERS

14.2.2.2.1.1.1. MARKET VALUE (USD MILLION)

14.2.2.2.1.1.2. MARKET VOLUME (UNITS)

14.2.2.2.1.1.3. AVERAGE SELLING PRICE (USD)

14.2.2.2.1.2 ELECTROLYTE ANALYZERS

14.2.2.2.1.2.1. MARKET VALUE (USD MILLION)

14.2.2.2.1.2.2. MARKET VOLUME (UNITS)

14.2.2.2.1.2.3. AVERAGE SELLING PRICE (USD)

14.2.2.2.1.3 COMBINED ANALYZERS

14.2.2.2.1.3.1. MARKET VALUE (USD MILLION)

14.2.2.2.1.3.2. MARKET VOLUME (UNITS)

14.2.2.2.1.3.3. AVERAGE SELLING PRICE (USD)

14.2.2.2.2. PORTABLE

14.2.2.2.2.1 BLOOD GAS ANALYZERS

14.2.2.2.2.1.1. MARKET VALUE (USD MILLION)

14.2.2.2.2.1.2. MARKET VOLUME (UNITS)

14.2.2.2.2.1.3. AVERAGE SELLING PRICE (USD)

14.2.2.2.2.2 ELECTROLYTE ANALYZERS

14.2.2.2.2.2.1. MARKET VALUE (USD MILLION)

14.2.2.2.2.2.2. MARKET VOLUME (UNITS)

14.2.2.2.2.2.3. AVERAGE SELLING PRICE (USD)

14.2.2.2.2.3 COMBINED ANALYZERS

14.2.2.2.2.3.1. MARKET VALUE (USD MILLION)

14.2.2.2.2.3.2. MARKET VOLUME (UNITS)

14.2.2.2.2.3.3. AVERAGE SELLING PRICE (USD)

14.2.3 HBA1C TESTING PRODUCTS

14.2.3.1. HBA1C TESTING INSTRUMENTS

14.2.3.1.1. MARKET VALUE (USD MILLION)

14.2.3.1.2. MARKET VOLUME (UNITS)

14.2.3.1.3. AVERAGE SELLING PRICE (USD)

14.2.3.2. HBA1C TESTING CONSUMABLES

14.2.3.2.1. MARKET VALUE (USD MILLION)

14.2.3.2.2. MARKET VOLUME (UNITS)

14.2.3.2.3. AVERAGE SELLING PRICE (USD)

14.2.4 POC ANALYSER

14.2.4.1. MARKET VALUE (USD MILLION)

14.2.4.2. MARKET VOLUME (UNITS)

14.2.4.3. AVERAGE SELLING PRICE (USD)

14.2.5 ECG DEVICE

14.2.5.1. RESTING ECG DEVICES

14.2.5.1.1. MARKET VALUE (USD MILLION)

14.2.5.1.2. MARKET VOLUME (UNITS)

14.2.5.1.3. AVERAGE SELLING PRICE (USD)

14.2.5.2. STRESS ECG DEVICES

14.2.5.2.1. MARKET VALUE (USD MILLION)

14.2.5.2.2. MARKET VOLUME (UNITS)

14.2.5.2.3. AVERAGE SELLING PRICE (USD)

14.2.5.3. HOLTER MONITORS

14.2.5.3.1. MARKET VALUE (USD MILLION)

14.2.5.3.2. MARKET VOLUME (UNITS)

14.2.5.3.3. AVERAGE SELLING PRICE (USD)

14.2.6 OTHERS

14.3 GLUCOSE MONITORING PRODUCTS

14.3.1 STRIPS

14.3.1.1. MARKET VALUE (USD MILLION)

14.3.1.2. MARKET VOLUME (UNITS)

14.3.1.3. AVERAGE SELLING PRICE (USD)

14.3.2 METERS

14.3.2.1. MARKET VALUE (USD MILLION)

14.3.2.2. MARKET VOLUME (UNITS)

14.3.2.3. AVERAGE SELLING PRICE (USD)

14.3.3 LANCETS & LANCING DEVICES

14.3.3.1. MARKET VALUE (USD MILLION)

14.3.3.2. MARKET VOLUME (UNITS)

14.3.3.3. AVERAGE SELLING PRICE (USD)

14.4 INFECTIOUS DISEASE TESTING PRODUCTS

14.4.1 INFLUENZA TESTING PRODUCTS

14.4.1.1. TRADITIONAL DIAGNOSTIC TEST

14.4.1.1.1. RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)

14.4.1.1.1.1 MARKET VALUE (USD MILLION)

14.4.1.1.1.2 MARKET VOLUME (UNITS)

14.4.1.1.1.3 AVERAGE SELLING PRICE (USD)

14.4.1.1.2. DIRECT FLUORESCENT ANTIBODY TEST (DFAT)

14.4.1.1.2.1 MARKET VALUE (USD MILLION)

14.4.1.1.2.2 MARKET VOLUME (UNITS)

14.4.1.1.2.3 AVERAGE SELLING PRICE (USD)

14.4.1.1.3. VIRAL CULTURE

14.4.1.1.3.1 MARKET VALUE (USD MILLION)

14.4.1.1.3.2 MARKET VOLUME (UNITS)

14.4.1.1.3.3 AVERAGE SELLING PRICE (USD)

14.4.1.1.4. SEROLOGICAL ASSAY

14.4.1.1.4.1 MARKET VALUE (USD MILLION)

14.4.1.1.4.2 MARKET VOLUME (UNITS)

14.4.1.1.4.3 AVERAGE SELLING PRICE (USD)

14.4.1.2. MOLECULAR DIAGNOSTIC ASSAY

14.4.1.2.1. RT-PCR

14.4.1.2.1.1 MARKET VALUE (USD MILLION)

14.4.1.2.1.2 MARKET VOLUME (UNITS)

14.4.1.2.1.3 AVERAGE SELLING PRICE (USD)

14.4.1.2.2. LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)

14.4.1.2.2.1 MARKET VALUE (USD MILLION)

14.4.1.2.2.2 MARKET VOLUME (UNITS)

14.4.1.2.2.3 AVERAGE SELLING PRICE (USD)

14.4.1.2.3. NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT)

14.4.1.2.3.1 MARKET VALUE (USD MILLION)

14.4.1.2.3.2 MARKET VOLUME (UNITS)

14.4.1.2.3.3 AVERAGE SELLING PRICE (USD)

14.4.1.2.4. SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)

14.4.1.2.4.1 MARKET VALUE (USD MILLION)

14.4.1.2.4.2 MARKET VOLUME (UNITS)

14.4.1.2.4.3 AVERAGE SELLING PRICE (USD)

14.4.1.2.5. OTHERS

14.4.2 HIV TESTING PRODUCTS

14.4.2.1. TESTING EQUIPMENT

14.4.2.1.1. MARKET VALUE (USD MILLION)

14.4.2.1.2. MARKET VOLUME (UNITS)

14.4.2.1.3. AVERAGE SELLING PRICE (USD)

14.4.2.2. TESTING REAGENT

14.4.2.2.1. MARKET VALUE (USD MILLION)

14.4.2.2.2. MARKET VOLUME (UNITS)

14.4.2.2.3. AVERAGE SELLING PRICE (USD)

14.4.3 HEPATITIS C TESTING PRODUCTS

14.4.3.1. HCV ANTIBODY TESTS

14.4.3.1.1. MARKET VALUE (USD MILLION)

14.4.3.1.2. MARKET VOLUME (UNITS)

14.4.3.1.3. AVERAGE SELLING PRICE (USD)

14.4.3.2. HCV VIRAL LOAD TESTS

14.4.3.2.1. MARKET VALUE (USD MILLION)

14.4.3.2.2. MARKET VOLUME (UNITS)

14.4.3.2.3. AVERAGE SELLING PRICE (USD)

14.4.3.3. OTHER TESTS

14.4.4 SEXUALLY TRANSMITTED DISEASE (STD) TESTING

14.4.4.1. NAAT-BASED SYSTEMS

14.4.4.1.1. MARKET VALUE (USD MILLION)

14.4.4.1.2. MARKET VOLUME (UNITS)

14.4.4.1.3. AVERAGE SELLING PRICE (USD)

14.4.4.2. NON–NAAT-BASED SYSTEMS

14.4.4.2.1. MARKET VALUE (USD MILLION)

14.4.4.2.2. MARKET VOLUME (UNITS)

14.4.4.2.3. AVERAGE SELLING PRICE (USD)

14.4.5 HEALTHCARE-ASSOCIATED INFECTION (HAI) TESTING

14.4.5.1. MARKET VALUE (USD MILLION)

14.4.5.2. MARKET VOLUME (UNITS)

14.4.5.3. AVERAGE SELLING PRICE (USD)

14.4.6 RESPIRATORY INFECTION TESTING PRODUCTS

14.4.6.1. MARKET VALUE (USD MILLION)

14.4.6.2. MARKET VOLUME (UNITS)

14.4.6.3. AVERAGE SELLING PRICE (USD)

14.4.7 TROPICAL DISEASE TESTING PRODUCTS

14.4.7.1. MARKET VALUE (USD MILLION)

14.4.7.2. MARKET VOLUME (UNITS)

14.4.7.3. AVERAGE SELLING PRICE (USD)

14.4.8 COVID-19

14.4.8.1. MARKET VALUE (USD MILLION)

14.4.8.2. MARKET VOLUME (UNITS)

14.4.8.3. AVERAGE SELLING PRICE (USD)

14.4.9 OTHER INFECTIOUS DISEASE TESTING PRODUCTS

14.5 COAGULATION MONITORING PRODUCTS

14.5.1 ANTICOAGULATION MONITORING DEVICES

14.5.1.1. PROTHROMBIN TIME/INTERNATIONAL NORMALIZED RATIO (PT-INR) TESTING DEVICES

14.5.1.1.1. MARKET VALUE (USD MILLION)

14.5.1.1.2. MARKET VOLUME (UNITS)

14.5.1.1.3. AVERAGE SELLING PRICE (USD)

14.5.1.2. ACTIVATED CLOTTING TIME (ACT)

14.5.1.2.1. MARKET VALUE (USD MILLION)

14.5.1.2.2. MARKET VOLUME (UNITS)

14.5.1.2.3. AVERAGE SELLING PRICE (USD)

14.5.1.3. ACTIVATED PARTIAL THROMBOPLASTIN TIME (APPT)

14.5.1.3.1. MARKET VALUE (USD MILLION)

14.5.1.3.2. MARKET VOLUME (UNITS)

14.5.1.3.3. AVERAGE SELLING PRICE (USD)

14.5.2 PLATELET FUNCTION MONITORING DEVICES

14.5.2.1. MARKET VALUE (USD MILLION)

14.5.2.2. MARKET VOLUME (UNITS)

14.5.2.3. AVERAGE SELLING PRICE (USD)

14.5.3 VISCOELASTIC COAGULATION MONITORING DEVICES

14.5.3.1. THROMBOELASTOGRAPHY (TEG)

14.5.3.1.1. MARKET VALUE (USD MILLION)

14.5.3.1.2. MARKET VOLUME (UNITS)

14.5.3.1.3. AVERAGE SELLING PRICE (USD)

14.5.3.2. ROTATIONAL THROMBOELASTOMETRY (ROTEM)

14.5.3.2.1. MARKET VALUE (USD MILLION)

14.5.3.2.2. MARKET VOLUME (UNITS)

14.5.3.2.3. AVERAGE SELLING PRICE (USD)

14.5.4 OTHERS

14.6 PREGNANCY & FERTILITY TESTING PRODUCTS

14.6.1 PREGNANCY TESTING PRODUCTS

14.6.1.1. PREGNANCY TESTING , BY PRODUCT TYPE

14.6.1.1.1. STRIPS/ DIP STICKS AND CARDS

14.6.1.1.1.1 MARKET VALUE (USD MILLION)

14.6.1.1.1.2 MARKET VOLUME (UNITS)

14.6.1.1.1.3 AVERAGE SELLING PRICE (USD)

14.6.1.1.2. MID STREAM DEVICES

14.6.1.1.2.1 MARKET VALUE (USD MILLION)

14.6.1.1.2.2 MARKET VOLUME (UNITS)

14.6.1.1.2.3 AVERAGE SELLING PRICE (USD)

14.6.1.1.3. CASSETTES

14.6.1.1.3.1 MARKET VALUE (USD MILLION)

14.6.1.1.3.2 MARKET VOLUME (UNITS)

14.6.1.1.3.3 AVERAGE SELLING PRICE (USD)

14.6.1.1.4. DIGITAL DEVICES

14.6.1.1.4.1 MARKET VALUE (USD MILLION)

14.6.1.1.4.2 MARKET VOLUME (UNITS)

14.6.1.1.4.3 AVERAGE SELLING PRICE (USD)

14.6.1.1.5. LINE-INDICATOR DEVICES

14.6.1.1.5.1 MARKET VALUE (USD MILLION)

14.6.1.1.5.2 MARKET VOLUME (UNITS)

14.6.1.1.5.3 AVERAGE SELLING PRICE (USD)

14.6.1.2. PREGNANCY TESTING, BY TEST TYPE

14.6.1.2.1. FSH URINE TEST

14.6.1.2.1.1 MARKET VALUE (USD MILLION)

14.6.1.2.1.2 MARKET VOLUME (UNITS)

14.6.1.2.1.3 AVERAGE SELLING PRICE (USD)

14.6.1.2.2. LUTEINIZING HORMONE (LH) URINE TEST

14.6.1.2.2.1 MARKET VALUE (USD MILLION)

14.6.1.2.2.2 MARKET VOLUME (UNITS)

14.6.1.2.2.3 AVERAGE SELLING PRICE (USD)

14.6.1.2.3. HUMAN CHORIONIC GONADOTROPIN (HCG) BLOOD/SERUM TEST

14.6.1.2.3.1 MARKET VALUE (USD MILLION)

14.6.1.2.3.2 MARKET VOLUME (UNITS)

14.6.1.2.3.3 AVERAGE SELLING PRICE (USD)

14.6.1.2.4. HCG URINE TEST

14.6.1.2.4.1 MARKET VALUE (USD MILLION)

14.6.1.2.4.2 MARKET VOLUME (UNITS)

14.6.1.2.4.3 AVERAGE SELLING PRICE (USD)

14.6.2 FERTILITY TESTING PRODUCTS

14.6.2.1. HUMAN CHORIONIC GONADOTROPIN (HCG) URINE TEST

14.6.2.1.1. MARKET VALUE (USD MILLION)

14.6.2.1.2. MARKET VOLUME (UNITS)

14.6.2.1.3. AVERAGE SELLING PRICE (USD)

14.6.2.2. FSH URINE TEST

14.6.2.2.1. MARKET VALUE (USD MILLION)

14.6.2.2.2. MARKET VOLUME (UNITS)

14.6.2.2.3. AVERAGE SELLING PRICE (USD)

14.6.2.3. HUMAN CHORIONIC GONADOTROPIN (HCG) BLOOD TEST

14.6.2.3.1. MARKET VALUE (USD MILLION)

14.6.2.3.2. MARKET VOLUME (UNITS)

14.6.2.3.3. AVERAGE SELLING PRICE (USD)

14.6.2.4. LUTEINIZING HORMONE (LH) URINE TEST

14.6.2.4.1. MARKET VALUE (USD MILLION)

14.6.2.4.2. MARKET VOLUME (UNITS)

14.6.2.4.3. AVERAGE SELLING PRICE (USD)

14.7 TUMOR/CANCER MARKER TESTING PRODUCTS

14.7.1 MARKET VALUE (USD MILLION)

14.7.2 MARKET VOLUME (UNITS)

14.7.3 AVERAGE SELLING PRICE (USD)

14.8 URINALYSIS TESTING PRODUCTS

14.8.1 POC URINE STRIP SELF-TESTING

14.8.1.1. MARKET VALUE (USD MILLION)

14.8.1.2. MARKET VOLUME (UNITS)

14.8.1.3. AVERAGE SELLING PRICE (USD)

14.8.2 POC URINE TEST STRIP PROFESSIONAL TESTING

14.8.2.1. MARKET VALUE (USD MILLION)

14.8.2.2. MARKET VOLUME (UNITS)

14.8.2.3. AVERAGE SELLING PRICE (USD)

14.9 CHOLESTEROL TESTING PRODUCTS

14.9.1 INSTRUMENTS

14.9.1.1. TABLE-TOP ANALYZERS

14.9.1.1.1. MARKET VALUE (USD MILLION)

14.9.1.1.2. MARKET VOLUME (UNITS)

14.9.1.1.3. AVERAGE SELLING PRICE (USD)

14.9.1.2. HAND-HELD ANALYZERS

14.9.1.2.1. MARKET VALUE (USD MILLION)

14.9.1.2.2. MARKET VOLUME (UNITS)

14.9.1.2.3. AVERAGE SELLING PRICE (USD)

14.9.2 TESTING KITS

14.9.2.1. MARKET VALUE (USD MILLION)

14.9.2.2. MARKET VOLUME (UNITS)

14.9.2.3. AVERAGE SELLING PRICE (USD)

14.1 HEMATOLOGY TESTING PRODUCTS

14.10.1 MARKET VALUE (USD MILLION)

14.10.2 MARKET VOLUME (UNITS)

14.10.3 AVERAGE SELLING PRICE (USD)

14.11 DRUGS-OF-ABUSE (DOA) TESTING PRODUCTS

14.11.1 DOA ANALYSERS

14.11.1.1. IMMUNOASSAYS

14.11.1.1.1. MARKET VALUE (USD MILLION)

14.11.1.1.2. MARKET VOLUME (UNITS)

14.11.1.1.3. AVERAGE SELLING PRICE (USD)

14.11.1.2. CHROMATOGRAPHIC DEVICES

14.11.1.2.1. MARKET VALUE (USD MILLION)

14.11.1.2.2. MARKET VOLUME (UNITS)

14.11.1.2.3. AVERAGE SELLING PRICE (USD)

14.11.1.3. BREATH ANALYSERS

14.11.1.3.1. MARKET VALUE (USD MILLION)

14.11.1.3.2. MARKET VOLUME (UNITS)

14.11.1.3.3. AVERAGE SELLING PRICE (USD)

14.11.2 RAPID TESTING DEVICES

14.11.2.1. URINE TESTING DEVICES

14.11.2.1.1. MARKET VALUE (USD MILLION)

14.11.2.1.2. MARKET VOLUME (UNITS)

14.11.2.1.3. AVERAGE SELLING PRICE (USD)

14.11.2.2. ORAL FLUID TESTING DEVICES

14.11.2.2.1. MARKET VALUE (USD MILLION)

14.11.2.2.2. MARKET VOLUME (UNITS)

14.11.2.2.3. AVERAGE SELLING PRICE (USD)

14.11.3 OTHERS

14.12 FECAL OCCULT TESTING PRODUCTS

14.12.1 GUAIAC FOB STOOL TEST

14.12.1.1. MARKET VALUE (USD MILLION)

14.12.1.2. MARKET VOLUME (UNITS)

14.12.1.3. AVERAGE SELLING PRICE (USD)

14.12.2 IMMUNO-FOB AGGLUTINATION TEST

14.12.2.1. MARKET VALUE (USD MILLION)

14.12.2.2. MARKET VOLUME (UNITS)

14.12.2.3. AVERAGE SELLING PRICE (USD)

14.12.3 LATERAL FLOW IMMUNO-FOB TEST

14.12.3.1. MARKET VALUE (USD MILLION)

14.12.3.2. MARKET VOLUME (UNITS)

14.12.3.3. AVERAGE SELLING PRICE (USD)

14.12.4 IMMUNO-FOB ELISA TEST

14.12.4.1. MARKET VALUE (USD MILLION)

14.12.4.2. MARKET VOLUME (UNITS)

14.12.4.3. AVERAGE SELLING PRICE (USD)

14.13 OTHER POC PRODUCTS

15 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY APPLICATION

15.1 OVERVIEW

15.2 BLOOD TRANSFUSION

15.3 CARDIAC MONITORING

15.4 COAGULATION

15.5 BLOOD GLUCOSE

15.6 HAEMATOLOGY

15.7 NON- INVASIVE SPO2 MONITORING

15.8 NON- INVASIVE PCO2 MONITORING

15.9 WHOLE BLOOD ANALYSIS

15.1 VITAL SIGN MONITORING

15.11 OTHERS

16 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PLATFORM

16.1 OVERVIEW

16.2 LATERAL FLOW ASSAYS

16.3 IMMUNOCHROMATOGRAPHY TESTS

16.4 DIPSTICKS

16.5 MICROFLUIDICS

16.6 MOLECULAR DIAGNOSTICS

16.7 IMMUNOASSAYS

16.8 CLINICAL CHEMISTRY ASSAYS

16.9 HEMATOLOGY

16.1 OTHERS

17 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PRESCRIPTION MODE

17.1 OVERVIEW

17.2 PRESCRIPTION-BASED TESTING

17.3 OTC TESTING

18 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY TESTING LOCATION

18.1 OVERVIEW

18.2 LABORATORY BASED POINT-OF-CARE-TESTING (POCT)

18.3 AT-HOME POINT-OF-CARE-TESTING (POCT)

19 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY END USER

19.1 OVERVIEW

19.2 HOSPITAL

19.2.1 PRIVATE

19.2.1.1. TIER 1

19.2.1.2. TIER 2

19.2.1.3. TIER 3

19.2.2 PUBLIC

19.2.2.1. TIER 1

19.2.2.2. TIER 2

19.2.2.3. TIER 3

19.3 CLINICS

19.4 LABORATORIES

19.5 PATHOLOGY LABS

19.6 DIAGNOSTIC CENTER

19.7 HOME CARE

19.8 AMBULATORY SURGERY CENTERS

19.9 ELDERLY CARE CENTERS

19.1 OTHERS

20 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY DISTRIBUTION CHANNEL

20.1 OVERVIEW

20.2 DIRECT TENDER

20.3 RETAIL SALES

20.4 ONLINE SALES

20.5 OTHERS

21 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , SWOT AND DBMR ANALYSIS

22 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , COMPANY LANDSCAPE

22.1 COMPANY SHARE ANALYSIS: THAILAND

22.2 MERGERS & ACQUISITIONS

22.3 NEW PRODUCT DEVELOPMENT & APPROVALS

22.4 EXPANSIONS

22.5 REGULATORY CHANGES

22.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

23 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY REGION

Thailand Point-of-Care-Testing (POCT) Market , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

23.1 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

24 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , COMPANY PROFILE

24.1 F. HOFFMANN-LA ROCHE LTD

24.1.1 COMPANY OVERVIEW

24.1.2 REVENUE ANALYSIS

24.1.3 GEOGRAPHIC PRESENCE

24.1.4 PRODUCT PORTFOLIO

24.1.5 RECENT DEVELOPMENTS

24.2 SIEMENS HEALTHCARE GMBH

24.2.1 COMPANY OVERVIEW

24.2.2 REVENUE ANALYSIS

24.2.3 GEOGRAPHIC PRESENCE

24.2.4 PRODUCT PORTFOLIO

24.2.5 RECENT DEVELOPMENTS

24.3 ABBOTT

24.3.1 COMPANY OVERVIEW

24.3.2 REVENUE ANALYSIS

24.3.3 GEOGRAPHIC PRESENCE

24.3.4 PRODUCT PORTFOLIO

24.3.5 RECENT DEVELOPMENTS

24.4 BIOMÉRIEUX

24.4.1 COMPANY OVERVIEW

24.4.2 REVENUE ANALYSIS

24.4.3 GEOGRAPHIC PRESENCE

24.4.4 PRODUCT PORTFOLIO

24.4.5 RECENT DEVELOPMENTS

24.5 ACON LABORATORIES, INC.

24.5.1 COMPANY OVERVIEW

24.5.2 REVENUE ANALYSIS

24.5.3 GEOGRAPHIC PRESENCE

24.5.4 PRODUCT PORTFOLIO

24.5.5 RECENT DEVELOPMENTS

24.6 BIO-RAD LABORATORIES, INC

24.6.1 COMPANY OVERVIEW

24.6.2 REVENUE ANALYSIS

24.6.3 GEOGRAPHIC PRESENCE

24.6.4 PRODUCT PORTFOLIO

24.6.5 RECENT DEVELOPMENTS

24.7 WERFEN

24.7.1 COMPANY OVERVIEW

24.7.2 REVENUE ANALYSIS

24.7.3 GEOGRAPHIC PRESENCE

24.7.4 PRODUCT PORTFOLIO

24.7.5 RECENT DEVELOPMENTS

24.8 NOVA BIOMEDICAL

24.8.1 COMPANY OVERVIEW

24.8.2 REVENUE ANALYSIS

24.8.3 GEOGRAPHIC PRESENCE

24.8.4 PRODUCT PORTFOLIO

24.8.5 RECENT DEVELOPMENTS

24.9 PTS DIAGNOSTICS

24.9.1 COMPANY OVERVIEW

24.9.2 REVENUE ANALYSIS

24.9.3 GEOGRAPHIC PRESENCE

24.9.4 PRODUCT PORTFOLIO

24.9.5 RECENT DEVELOPMENTS

24.1 SEKISUI DIAGNOSTICS

24.10.1 COMPANY OVERVIEW

24.10.2 REVENUE ANALYSIS

24.10.3 GEOGRAPHIC PRESENCE

24.10.4 PRODUCT PORTFOLIO

24.10.5 RECENT DEVELOPMENTS

24.11 TRINITY BIOTECH

24.11.1 COMPANY OVERVIEW

24.11.2 REVENUE ANALYSIS

24.11.3 GEOGRAPHIC PRESENCE

24.11.4 PRODUCT PORTFOLIO

24.11.5 RECENT DEVELOPMENTS

24.12 DANAHER

24.12.1 COMPANY OVERVIEW

24.12.2 REVENUE ANALYSIS

24.12.3 GEOGRAPHIC PRESENCE

24.12.4 PRODUCT PORTFOLIO

24.12.5 RECENT DEVELOPMENTS

24.13 THERMO FISHER SCIENTIFIC INC

24.13.1 COMPANY OVERVIEW

24.13.2 REVENUE ANALYSIS

24.13.3 GEOGRAPHIC PRESENCE

24.13.4 PRODUCT PORTFOLIO

24.13.5 RECENT DEVELOPMENTS

24.14 MERIDIAN DIAGNOSTICS

24.14.1 COMPANY OVERVIEW

24.14.2 REVENUE ANALYSIS

24.14.3 GEOGRAPHIC PRESENCE

24.14.4 PRODUCT PORTFOLIO

24.14.5 RECENT DEVELOPMENTS

24.15 BD

24.15.1 COMPANY OVERVIEW

24.15.2 REVENUE ANALYSIS

24.15.3 GEOGRAPHIC PRESENCE

24.15.4 PRODUCT PORTFOLIO

24.15.5 RECENT DEVELOPMENTS

24.16 SYSMEX (THAILAND) CO., LTD

24.16.1 COMPANY OVERVIEW

24.16.2 REVENUE ANALYSIS

24.16.3 GEOGRAPHIC PRESENCE

24.16.4 PRODUCT PORTFOLIO

24.16.5 RECENT DEVELOPMENTS

24.17 FUJIFILM THAILAND LTD.

24.17.1 COMPANY OVERVIEW

24.17.2 REVENUE ANALYSIS

24.17.3 GEOGRAPHIC PRESENCE

24.17.4 PRODUCT PORTFOLIO

24.17.5 RECENT DEVELOPMENTS

25 RELATED REPORTS

26 CONCLUSION

27 QUESTIONNAIRE

28 ABOUT DATA BRIDGE MARKET RESEARCH